ORBIMED ADVISORS LLC - 06 Feb 2025 Form 3 Insider Report for Sionna Therapeutics, Inc. (SION)

Role
Director
Signature
/s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
Issuer symbol
SION
Transactions as of
06 Feb 2025
Net transactions value
$0
Form type
3
Filing time
06 Feb 2025, 21:18:19 UTC
Previous filing
14 Jan 2025
Next filing
10 Feb 2025

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SION Series B convertible preferred stock 06 Feb 2025 Common Stock 1,752,755 See footnotes F1, F2, F3
holding SION Series C convertible preferred stock 06 Feb 2025 Common Stock 1,402,204 See footnotes F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") is convertible into Common Stock on a one-for-1.4611 basis at the option of the holder, and will convert automatically upon the closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. The Preferred Stock has no expiration date.
F2 These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors LLC ("Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
F3 This report on Form 4 is jointly filed by Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. Advisors has designated a representative, Peter A. Thompson, a member of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.